FDA Investigates Med Prep Consulting for Contaminated Intravenous Solution - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Investigates Med Prep Consulting for Contaminated Intravenous Solution


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA alerted healthcare providers and patients of a voluntary, nationwide recall of all sterile drug products from Med Prep Consulting, a specialty compounding pharmacy licensed by the state of New Jersey, in a March 18, 2013 FDA press release. Med Prep Consulting initiated the recall because fungus particles were identified in bags of magnesium sulfate intravenous solution after healthcare providers at a hospital in Connecticut observed the floating particles. The New Jersey State Board of Pharmacy entered into an interim voluntary consent order with Med Prep Consulting, under which the company temporarily halted all production operations.

“Giving a patient a contaminated injectable drug could result in a life-threatening infection,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, in the press release. “We do not have reports of patient infections. However, due to a lack of sterility assurance at the facility and out of an abundance of caution, this recall is necessary to protect patients.” FDA’s investigation is ongoing, and FDA is working with the Centers for Disease Control and Prevention and state officials in New Jersey and Connecticut to determine the scope of the contamination.

Med Prep Consulting’s Tinton Falls, NJ facility prepares sterile products for intravenous administration in hospitals and physician’s offices or clinics.

Last year’s fatal fungal meningitis outbreak was attributed to lack of sterility assurance in injectable products produced by a compounding pharmacy in Massachusetts.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
41%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here